AU703473B2 - Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions - Google Patents

Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions Download PDF

Info

Publication number: AU703473B2
Authority: AU; Australia
Prior art keywords: compound; optionally substituted; alkyl; ring; independently selected
Prior art date: 1996-02-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU14979/97A

Other languages

English (en)

Other versions

AU1497997A (en

Inventor

David B. Maclean

David D. Thompson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Corp SRL

Original Assignee

Pfizer Corp Belgium

Pfizer Corp SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-28

Filing date

1997-02-27

Publication date

1999-03-25

1997-02-27 Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium

1997-09-04 Publication of AU1497997A publication Critical patent/AU1497997A/en

1999-03-25 Application granted granted Critical

1999-03-25 Publication of AU703473B2 publication Critical patent/AU703473B2/en

2017-02-27 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

229940011871 estrogen Drugs 0.000 title claims abstract description 59
239000000262 estrogen Substances 0.000 title claims abstract description 59
230000001575 pathological effect Effects 0.000 title claims abstract description 39
239000000556 agonist Substances 0.000 title claims abstract description 21
230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
239000000328 estrogen antagonist Substances 0.000 title claims description 19
150000001875 compounds Chemical class 0.000 claims abstract description 160
125000001424 substituent group Chemical group 0.000 claims abstract description 47
239000003814 drug Substances 0.000 claims abstract description 25
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 13
210000004789 organ system Anatomy 0.000 claims abstract description 3
238000000034 method Methods 0.000 claims description 88
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 55
206010000496 acne Diseases 0.000 claims description 31
208000035475 disorder Diseases 0.000 claims description 31
208000002874 Acne Vulgaris Diseases 0.000 claims description 27
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
206010003694 Atrophy Diseases 0.000 claims description 24
230000037444 atrophy Effects 0.000 claims description 24
150000003839 salts Chemical class 0.000 claims description 24
-1 bicyclic amine Chemical class 0.000 claims description 23
125000000217 alkyl group Chemical group 0.000 claims description 22
125000005842 heteroatom Chemical group 0.000 claims description 22
208000007848 Alcoholism Diseases 0.000 claims description 21
206010012601 diabetes mellitus Diseases 0.000 claims description 21
125000000623 heterocyclic group Chemical group 0.000 claims description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
206010020112 Hirsutism Diseases 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 17
201000004384 Alopecia Diseases 0.000 claims description 16
230000001833 anti-estrogenic effect Effects 0.000 claims description 15
208000008742 seborrheic dermatitis Diseases 0.000 claims description 15
206010039792 Seborrhoea Diseases 0.000 claims description 14
230000003247 decreasing effect Effects 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 14
230000005764 inhibitory process Effects 0.000 claims description 14
206010001584 alcohol abuse Diseases 0.000 claims description 13
208000025746 alcohol use disease Diseases 0.000 claims description 13
229940046836 anti-estrogen Drugs 0.000 claims description 13
231100000360 alopecia Toxicity 0.000 claims description 12
201000000079 gynecomastia Diseases 0.000 claims description 12
208000030270 breast disease Diseases 0.000 claims description 11
229910052736 halogen Inorganic materials 0.000 claims description 11
150000002367 halogens Chemical group 0.000 claims description 11
230000002685 pulmonary effect Effects 0.000 claims description 11
206010020772 Hypertension Diseases 0.000 claims description 10
125000002837 carbocyclic group Chemical group 0.000 claims description 10
230000035558 fertility Effects 0.000 claims description 10
230000035935 pregnancy Effects 0.000 claims description 10
208000023275 Autoimmune disease Diseases 0.000 claims description 9
206010006187 Breast cancer Diseases 0.000 claims description 9
208000026310 Breast neoplasm Diseases 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 9
201000001421 hyperglycemia Diseases 0.000 claims description 9
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
208000026928 Turner syndrome Diseases 0.000 claims description 8
230000000391 smoking effect Effects 0.000 claims description 8
230000029663 wound healing Effects 0.000 claims description 8
201000003146 cystitis Diseases 0.000 claims description 7
230000003287 optical effect Effects 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 6
208000026278 immune system disease Diseases 0.000 claims description 6
125000001624 naphthyl group Chemical group 0.000 claims description 6
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
231100000252 nontoxic Toxicity 0.000 claims description 6
230000003000 nontoxic effect Effects 0.000 claims description 6
208000011580 syndromic disease Diseases 0.000 claims description 6
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
206010021639 Incontinence Diseases 0.000 claims description 5
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
208000004059 Male Breast Neoplasms Diseases 0.000 claims description 5
208000019695 Migraine disease Diseases 0.000 claims description 5
150000001204 N-oxides Chemical class 0.000 claims description 5
208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 5
125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
201000001881 impotence Diseases 0.000 claims description 5
201000003175 male breast cancer Diseases 0.000 claims description 5
208000010907 male breast carcinoma Diseases 0.000 claims description 5
201000001441 melanoma Diseases 0.000 claims description 5
206010027599 migraine Diseases 0.000 claims description 5
150000003242 quaternary ammonium salts Chemical class 0.000 claims description 5
229920006395 saturated elastomer Polymers 0.000 claims description 5
206010046766 uterine cancer Diseases 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
150000001412 amines Chemical class 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000004423 acyloxy group Chemical group 0.000 claims description 2
125000003282 alkyl amino group Chemical group 0.000 claims description 2
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
125000004414 alkyl thio group Chemical group 0.000 claims description 2
125000004663 dialkyl amino group Chemical group 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
229910052717 sulfur Inorganic materials 0.000 claims 2
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims 1
125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 claims 1
YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
125000003710 aryl alkyl group Chemical group 0.000 claims 1
VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical group [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 claims 1
125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
230000000694 effects Effects 0.000 description 57
210000003491 skin Anatomy 0.000 description 42
238000011282 treatment Methods 0.000 description 40
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
208000024891 symptom Diseases 0.000 description 31
238000003556 assay Methods 0.000 description 30
238000002560 therapeutic procedure Methods 0.000 description 26
241000700159 Rattus Species 0.000 description 24
201000010099 disease Diseases 0.000 description 24
210000002540 macrophage Anatomy 0.000 description 24
239000000203 mixture Substances 0.000 description 23
239000004480 active ingredient Substances 0.000 description 22
238000012360 testing method Methods 0.000 description 21
229940079593 drug Drugs 0.000 description 19
238000009472 formulation Methods 0.000 description 19
241001465754 Metazoa Species 0.000 description 17
230000007423 decrease Effects 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
230000001965 increasing effect Effects 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 14
229940068196 placebo Drugs 0.000 description 14
239000000902 placebo Substances 0.000 description 14
229960005309 estradiol Drugs 0.000 description 13
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 12
239000004615 ingredient Substances 0.000 description 12
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
230000009245 menopause Effects 0.000 description 12
230000001568 sexual effect Effects 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
229930182833 estradiol Natural products 0.000 description 11
230000006870 function Effects 0.000 description 11
230000009467 reduction Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
239000003054 catalyst Substances 0.000 description 10
210000003169 central nervous system Anatomy 0.000 description 10
238000011156 evaluation Methods 0.000 description 10
150000002632 lipids Chemical class 0.000 description 10
238000005259 measurement Methods 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
230000000875 corresponding effect Effects 0.000 description 9
210000004209 hair Anatomy 0.000 description 9
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 9
229960004622 raloxifene Drugs 0.000 description 9
239000003826 tablet Substances 0.000 description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
229920002472 Starch Polymers 0.000 description 8
102100040247 Tumor necrosis factor Human genes 0.000 description 8
239000013543 active substance Substances 0.000 description 8
201000007930 alcohol dependence Diseases 0.000 description 8
239000003242 anti bacterial agent Substances 0.000 description 8
229940088710 antibiotic agent Drugs 0.000 description 8
210000000481 breast Anatomy 0.000 description 8
239000002158 endotoxin Substances 0.000 description 8
239000012530 fluid Substances 0.000 description 8
239000008103 glucose Substances 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
208000002815 pulmonary hypertension Diseases 0.000 description 8
210000001732 sebaceous gland Anatomy 0.000 description 8
230000028327 secretion Effects 0.000 description 8
239000008107 starch Substances 0.000 description 8
235000019698 starch Nutrition 0.000 description 8
239000000126 substance Substances 0.000 description 8
241000282414 Homo sapiens Species 0.000 description 7
230000002378 acidificating effect Effects 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000008859 change Effects 0.000 description 7
210000000038 chest Anatomy 0.000 description 7
102000015694 estrogen receptors Human genes 0.000 description 7
108010038795 estrogen receptors Proteins 0.000 description 7
239000000583 progesterone congener Substances 0.000 description 7
229960001603 tamoxifen Drugs 0.000 description 7
206010006298 Breast pain Diseases 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
102000004877 Insulin Human genes 0.000 description 6
108090001061 Insulin Proteins 0.000 description 6
208000006662 Mastodynia Diseases 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000012636 effector Substances 0.000 description 6
230000036541 health Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000012442 inert solvent Substances 0.000 description 6
229940125396 insulin Drugs 0.000 description 6
230000003902 lesion Effects 0.000 description 6
229920006008 lipopolysaccharide Polymers 0.000 description 6
229910052744 lithium Inorganic materials 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
230000010412 perfusion Effects 0.000 description 6
230000008569 process Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
210000001215 vagina Anatomy 0.000 description 6
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 5
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 5
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
241000208125 Nicotiana Species 0.000 description 5
235000002637 Nicotiana tabacum Nutrition 0.000 description 5
208000001132 Osteoporosis Diseases 0.000 description 5
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
230000032683 aging Effects 0.000 description 5
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
230000004075 alteration Effects 0.000 description 5
239000003098 androgen Substances 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
239000002585 base Substances 0.000 description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000002537 cosmetic Substances 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000007123 defense Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
230000001076 estrogenic effect Effects 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000005984 hydrogenation reaction Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
229940127234 oral contraceptive Drugs 0.000 description 5
239000003539 oral contraceptive agent Substances 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000008092 positive effect Effects 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
238000011160 research Methods 0.000 description 5
239000000829 suppository Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000000454 talc Substances 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
235000012222 talc Nutrition 0.000 description 5
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
235000019155 vitamin A Nutrition 0.000 description 5
239000011719 vitamin A Substances 0.000 description 5
229940045997 vitamin a Drugs 0.000 description 5
208000019901 Anxiety disease Diseases 0.000 description 4
239000004342 Benzoyl peroxide Substances 0.000 description 4
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
241000699800 Cricetinae Species 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 4
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 4
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical group OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
206010033733 Papule Diseases 0.000 description 4
206010057249 Phagocytosis Diseases 0.000 description 4
206010064911 Pulmonary arterial hypertension Diseases 0.000 description 4
206010037888 Rash pustular Diseases 0.000 description 4
206010040047 Sepsis Diseases 0.000 description 4
206010040799 Skin atrophy Diseases 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
230000009471 action Effects 0.000 description 4
230000004913 activation Effects 0.000 description 4
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
229940030486 androgens Drugs 0.000 description 4
230000036506 anxiety Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
235000019400 benzoyl peroxide Nutrition 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
150000001805 chlorine compounds Chemical class 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
239000003433 contraceptive agent Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000000994 depressogenic effect Effects 0.000 description 4
230000035622 drinking Effects 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
238000009164 estrogen replacement therapy Methods 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
230000003676 hair loss Effects 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
229960005280 isotretinoin Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
230000008782 phagocytosis Effects 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000000843 powder Substances 0.000 description 4
201000008312 primary pulmonary hypertension Diseases 0.000 description 4
239000000047 product Substances 0.000 description 4
230000000750 progressive effect Effects 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
210000001147 pulmonary artery Anatomy 0.000 description 4
208000029561 pustule Diseases 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
150000003440 styrenes Chemical class 0.000 description 4
230000001629 suppression Effects 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
210000004291 uterus Anatomy 0.000 description 4
238000005303 weighing Methods 0.000 description 4
235000005074 zinc chloride Nutrition 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
201000009273 Endometriosis Diseases 0.000 description 3
208000001287 Galactorrhea Diseases 0.000 description 3
206010017600 Galactorrhoea Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920002683 Glycosaminoglycan Polymers 0.000 description 3
206010018473 Glycosuria Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
206010020649 Hyperkeratosis Diseases 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
208000007623 Lordosis Diseases 0.000 description 3
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
206010040954 Skin wrinkling Diseases 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000001548 androgenic effect Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000004872 arterial blood pressure Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229940124558 contraceptive agent Drugs 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
208000031513 cyst Diseases 0.000 description 3
210000000172 cytosol Anatomy 0.000 description 3
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 3
229960000452 diethylstilbestrol Drugs 0.000 description 3
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
229950004203 droloxifene Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
230000035780 glucosuria Effects 0.000 description 3
208000024963 hair loss Diseases 0.000 description 3
229910000042 hydrogen bromide Inorganic materials 0.000 description 3
229960002591 hydroxyproline Drugs 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
230000035800 maturation Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
230000016087 ovulation Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
210000004761 scalp Anatomy 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000009329 sexual behaviour Effects 0.000 description 3
239000000779 smoke Substances 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000000392 somatic effect Effects 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000010998 test method Methods 0.000 description 3
229960003604 testosterone Drugs 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
230000036325 urinary excretion Effects 0.000 description 3
229940124549 vasodilator Drugs 0.000 description 3
239000003071 vasodilator agent Substances 0.000 description 3
238000010626 work up procedure Methods 0.000 description 3
VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 2
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 2
GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 2
MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
208000019454 Feeding and Eating disease Diseases 0.000 description 2
206010016845 Foetal alcohol syndrome Diseases 0.000 description 2
206010017076 Fracture Diseases 0.000 description 2
201000001498 Froelich syndrome Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000006771 Gonadotropins Human genes 0.000 description 2
108010086677 Gonadotropins Proteins 0.000 description 2
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
208000007976 Ketosis Diseases 0.000 description 2
206010024870 Loss of libido Diseases 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241000699673 Mesocricetus auratus Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
206010056264 Obsessive rumination Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
208000012641 Pigmentation disease Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102100024028 Progonadoliberin-1 Human genes 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
206010039163 Right ventricular failure Diseases 0.000 description 2
208000000924 Right ventricular hypertrophy Diseases 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
208000010320 Sexual Infantilism Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
VFHDCDDYMMQCBF-UHFFFAOYSA-M [Cl-].[Zn+]C1=CC=CC=C1 Chemical class [Cl-].[Zn+]C1=CC=CC=C1 VFHDCDDYMMQCBF-UHFFFAOYSA-M 0.000 description 2
230000007488 abnormal function Effects 0.000 description 2
239000004015 abortifacient agent Substances 0.000 description 2
231100000641 abortifacient agent Toxicity 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940094957 androgens and estrogen Drugs 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000000035 biogenic effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
244000309464 bull Species 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
235000019504 cigarettes Nutrition 0.000 description 2
238000011461 current therapy Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
ZONSVLURFASOJK-LLAGZRPASA-N dehydromonocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3C2=C1C=C3 ZONSVLURFASOJK-LLAGZRPASA-N 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
125000001033 ether group Chemical group 0.000 description 2
230000029142 excretion Effects 0.000 description 2
210000005002 female reproductive tract Anatomy 0.000 description 2
230000004720 fertilization Effects 0.000 description 2
208000026934 fetal alcohol spectrum disease Diseases 0.000 description 2
201000007794 fetal alcohol syndrome Diseases 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
230000003325 follicular Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
208000002566 gonadal dysgenesis Diseases 0.000 description 2
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
239000002622 gonadotropin Substances 0.000 description 2
230000036449 good health Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
150000002537 isoquinolines Chemical class 0.000 description 2
230000000366 juvenile effect Effects 0.000 description 2
230000006651 lactation Effects 0.000 description 2
239000006210 lotion Substances 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000002175 menstrual effect Effects 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
VDCLSGXZVUDARN-UHFFFAOYSA-N molecular bromine;pyridine;hydrobromide Chemical compound Br.BrBr.C1=CC=NC=C1 VDCLSGXZVUDARN-UHFFFAOYSA-N 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229910000510 noble metal Inorganic materials 0.000 description 2
230000000269 nucleophilic effect Effects 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
244000039328 opportunistic pathogen Species 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
238000012261 overproduction Methods 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
210000003024 peritoneal macrophage Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical class OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000003880 polar aprotic solvent Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
208000005333 pulmonary edema Diseases 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000011867 re-evaluation Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000005000 reproductive tract Anatomy 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
241000894007 species Species 0.000 description 2
239000000934 spermatocidal agent Substances 0.000 description 2
230000001150 spermicidal effect Effects 0.000 description 2
229960002256 spironolactone Drugs 0.000 description 2
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
230000003797 telogen phase Effects 0.000 description 2
150000003511 tertiary amides Chemical class 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
230000007306 turnover Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000001836 utereotrophic effect Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
239000005526 vasoconstrictor agent Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
230000037303 wrinkles Effects 0.000 description 2
210000000707 wrist Anatomy 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical class C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
HMGCGUWFPZVPEK-UHFFFAOYSA-N 2-naphthalen-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 HMGCGUWFPZVPEK-UHFFFAOYSA-N 0.000 description 1
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
BFOCPTPKKJLPHX-UHFFFAOYSA-N 6-phenyl-5-[6-(2-pyrrolidin-1-ylethoxy)pyridin-3-yl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1CC2=CC(O)=CC=C2C(C=2C=NC(OCCN3CCCC3)=CC=2)C1C1=CC=CC=C1 BFOCPTPKKJLPHX-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
SSTODPPMEPQZQJ-UHFFFAOYSA-N 8-amino-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1CC(O)CC2=C1C=CC=C2N SSTODPPMEPQZQJ-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010063746 Accidental death Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000020154 Acnes Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
208000027559 Appetite disease Diseases 0.000 description 1
206010003439 Artificial menopause Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000004652 Cardiovascular Abnormalities Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000014882 Carotid artery disease Diseases 0.000 description 1
229910052684 Cerium Inorganic materials 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
206010010219 Compulsions Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010011219 Costochondritis Diseases 0.000 description 1
206010011486 Cryptococcal infections Diseases 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
208000001840 Dandruff Diseases 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
206010012205 Delayed puberty Diseases 0.000 description 1
208000034423 Delivery Diseases 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
240000001879 Digitalis lutea Species 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
208000004483 Dyspareunia Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
208000007984 Female Infertility Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000007522 Fused Kidney Diseases 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019629 Hepatic adenoma Diseases 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
206010020046 High arched palate Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
206010020524 Hydronephrosis Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020864 Hypertrichosis Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010021928 Infertility female Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
208000017924 Klinefelter Syndrome Diseases 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010025282 Lymphoedema Diseases 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
208000007466 Male Infertility Diseases 0.000 description 1
208000035450 Malformed Nails Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
208000017657 Menopausal disease Diseases 0.000 description 1
208000037093 Menstruation Disturbances Diseases 0.000 description 1
206010027387 Merycism Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
208000003250 Mixed connective tissue disease Diseases 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100046526 Mus musculus Tnf gene Proteins 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
208000021908 Myocardial disease Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
108070000018 Neuropeptide receptor Proteins 0.000 description 1
102000028517 Neuropeptide receptor Human genes 0.000 description 1
108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
241001134446 Niveas Species 0.000 description 1
206010054107 Nodule Diseases 0.000 description 1
206010029897 Obsessive thoughts Diseases 0.000 description 1
208000011623 Obstructive Lung disease Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000031816 Pathologic Dilatation Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
241001482237 Pica Species 0.000 description 1
208000009077 Pigmented Nevus Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
241000233870 Pneumocystis Species 0.000 description 1
206010035660 Pneumocystis Infections Diseases 0.000 description 1
208000025598 Pneumocystis infectious disease Diseases 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010068033 Renal fusion anomaly Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
206010041541 Spinal compression fracture Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
102000012607 Thrombomodulin Human genes 0.000 description 1
108010079274 Thrombomodulin Proteins 0.000 description 1
208000026317 Tietze syndrome Diseases 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
206010067269 Uterine fibrosis Diseases 0.000 description 1
241001227561 Valgus Species 0.000 description 1
210000001766 X chromosome Anatomy 0.000 description 1
ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000011366 aggressive therapy Methods 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003509 anti-fertility effect Effects 0.000 description 1
230000000708 anti-progestin effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940124572 antihypotensive agent Drugs 0.000 description 1
239000003418 antiprogestin Substances 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
150000001543 aryl boronic acids Chemical class 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
201000004988 autoimmune vasculitis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
208000021654 bicuspid aortic valve disease Diseases 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
208000037876 carotid Atherosclerosis Diseases 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
208000007287 cheilitis Diseases 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
125000004965 chloroalkyl group Chemical group 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
230000037411 cognitive enhancing Effects 0.000 description 1
230000001113 coital effect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000006264 debenzylation reaction Methods 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
210000000188 diaphragm Anatomy 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
229940064790 dilantin Drugs 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000009429 distress Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000004590 drinking behavior Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000001544 dysphoric effect Effects 0.000 description 1
210000000613 ear canal Anatomy 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000012173 estrus Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000004149 ethanol metabolism Effects 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
210000004709 eyebrow Anatomy 0.000 description 1
239000003925 fat Substances 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000003709 fluoroalkyl group Chemical group 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
208000020694 gallbladder disease Diseases 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
230000000910 hyperinsulinemic effect Effects 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
230000001096 hypoplastic effect Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000037451 immune surveillance Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
230000007803 itching Effects 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
208000011379 keloid formation Diseases 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000000244 kidney pelvis Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000013016 learning Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
208000013433 lightheadedness Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000006138 lithiation reaction Methods 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
208000002502 lymphedema Diseases 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000006883 memory enhancing effect Effects 0.000 description 1
210000004914 menses Anatomy 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960004023 minocycline Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
208000030454 monosomy Diseases 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229950002366 nafoxidine Drugs 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229920000847 nonoxynol Polymers 0.000 description 1
AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
229940066429 octoxynol Drugs 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
229950009215 phenylbutanoic acid Drugs 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
208000006155 precocious puberty Diseases 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000009430 psychological distress Effects 0.000 description 1
230000004800 psychological effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
210000003492 pulmonary vein Anatomy 0.000 description 1
239000008213 purified water Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000012048 reactive intermediate Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
208000000029 referred pain Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000246 remedial effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
208000015212 rumination disease Diseases 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
201000008662 sclerosing adenosis of breast Diseases 0.000 description 1
206010039722 scoliosis Diseases 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000008786 sensory perception of smell Effects 0.000 description 1
210000003765 sex chromosome Anatomy 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
239000002453 shampoo Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000009759 skin aging Effects 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
244000005714 skin microbiome Species 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000021259 spicy food Nutrition 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000009120 supportive therapy Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
231100000462 teratogen Toxicity 0.000 description 1
239000003439 teratogenic agent Substances 0.000 description 1
KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940126702 topical medication Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical group COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000011121 vaginal smear Methods 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
229940071104 xylenesulfonate Drugs 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Addiction (AREA)
Gynecology & Obstetrics (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hematology (AREA)
Pregnancy & Childbirth (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Hydrogenated Pyridines (AREA)

AU14979/97A 1996-02-28 1997-02-27 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions Ceased AU703473B2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1321296P	1996-02-28	1996-02-28
US013212		1996-02-28

Publications (2)

Publication Number	Publication Date
AU1497997A AU1497997A (en)	1997-09-04
AU703473B2 true AU703473B2 (en)	1999-03-25

Family

ID=21758830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU14979/97A Ceased AU703473B2 (en)	1996-02-28	1997-02-27	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

Country Status (16)

Country	Link
US (8)	US6107331A (de)
EP (2)	EP1106179B1 (de)
JP (1)	JPH107563A (de)
KR (1)	KR970061254A (de)
CN (2)	CN1122513C (de)
AT (2)	ATE396728T1 (de)
AU (1)	AU703473B2 (de)
CA (1)	CA2198578C (de)
DE (2)	DE69738740D1 (de)
DK (2)	DK1106179T3 (de)
ES (2)	ES2159811T3 (de)
GR (1)	GR3036583T3 (de)
IL (2)	IL120266A (de)
MY (1)	MY125602A (de)
PT (2)	PT1106179E (de)
ZA (1)	ZA971714B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU784439B2 (en) *	2000-01-12	2006-04-06	Pfizer Products Inc.	Compositions and methods of treatment for conditions responsive to testosterone elevation

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL120266A (en)	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP1027057A4 (de) *	1997-10-28	2003-01-02	Vivus Inc	Behandlung von weibliche sexuelle störungen
US6326392B1 (en)	1997-11-06	2001-12-04	American Home Products Corporation	Anti-estrogen plus progestin containing oral contraceptives
UA68365C2 (en) *	1997-11-06	2004-08-16	Wyeth Corp	Peroral contraception by combination of anti-estrogen and progestin
EP1004306A3 (de) *	1998-08-06	2000-06-07	Pfizer Products Inc.	Estrogen Agonisten/Antagonisten
TR200403328T2 (tr) *	1999-07-06	2005-03-21	Endorecherche, Inc.	Kilo alımını tedavi ve/veya önleme metotları.
US6436977B1 (en)	1999-09-29	2002-08-20	Pfizer Inc.	Dosing regimens for lasofoxifene
EP1113007A1 (de) *	1999-12-24	2001-07-04	Pfizer Inc.	Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
CO5271709A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5251465A1 (es)	2000-01-26	2003-02-28	Pfizer Prod Inc	Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
CA2405070A1 (en)	2000-04-07	2001-10-18	Pfizer Products Inc.	Estrogen agonist/antagonist metabolites
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
ATE346159T1 (de) *	2000-05-08	2006-12-15	Pfizer Prod Inc	Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
DE10039199A1 (de) *	2000-08-10	2002-02-21	Schering Ag	Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
IL145838A (en) *	2000-10-16	2008-11-03	Pfizer Prod Inc	Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
IL145876A0 (en)	2000-10-17	2002-07-25	Pfizer Prod Inc	Methods and kits for improving vascular health
AU781168B2 (en)	2001-01-26	2005-05-12	Pfizer Products Inc.	Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) *	2001-04-25	2002-10-31	Pfizer Products Inc.	Methods and kits for treating depression or preventing deterioration of cognitive function
UA75135C2 (en) *	2001-05-01	2006-03-15	Pfizer Prod Inc	Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
WO2003011282A1 (en) *	2001-07-31	2003-02-13	Pfizer Products Inc.	Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2003055856A2 (en) *	2001-10-17	2003-07-10	Bristol-Myers Squibb Company	BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
CA2496618A1 (en) *	2002-05-23	2003-12-04	Michael Holick	Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
ES2263072T3 (es) *	2002-12-18	2006-12-01	Laboratoires Besins International	Tratamiento de la mastalgia con 4-hidroxi tamoxifeno.
WO2005018575A2 (en) *	2003-08-26	2005-03-03	Board Of Regents, The University Of Texas System	Estrogen receptor modulators and uses thereof
US20050119276A1 (en) *	2003-09-24	2005-06-02	Wyeth	Methods of treating inflammatory bowel disease using NF-kB inhibitors
US7968532B2 (en) *	2003-12-15	2011-06-28	Besins Healthcare Luxembourg	Treatment of gynecomastia with 4-hydroxy tamoxifen
US20060079522A1 (en) *	2004-10-08	2006-04-13	Marzabadi Mohammad R	Amino substituted aryloxybenzylpiperidine derivatives
WO2006042172A2 (en) *	2004-10-09	2006-04-20	The Regents Of The University Of Michigan	Gender differences in experimental aortic aneurysm formation
DK1802312T3 (en)	2004-10-20	2015-12-14	Endorech Inc	Kønssteroidudgangsstof in combination with a selective estrogen receptor modulator for the prevention and treatment of vaginal atrophy in post-menopausal women
US8524663B2 (en)	2006-03-03	2013-09-03	New York University	Method for site-specific polyvalent display on polymers
KR20090029237A (ko) *	2006-06-02	2009-03-20	피어 트리 파머슈티칼스 인코포레이티드	위축성 질염을 치료하는 방법
WO2008076870A2 (en) *	2006-12-14	2008-06-26	Cady Roger K	Method and system for interactive cognitive testing
WO2009039344A1 (en) *	2007-09-21	2009-03-26	Harry Fisch	Treatment of migraine headaches using antiestrogens
US8784872B2 (en) *	2007-11-19	2014-07-22	Comgenrx, Inc.	Formulation for decreasing tobacco, alcohol, drug or food consumption
US20100104614A1 (en) *	2008-06-27	2010-04-29	Oronsky Bryan T	Providone compositions for wound healing
WO2012068284A2 (en) *	2010-11-16	2012-05-24	Baylor University	Efficient method for preparing functionalized benzosuberenes
US9744177B2 (en) *	2014-03-10	2017-08-29	Endorecherche, Inc.	Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CN109803651B (zh)	2016-06-27	2022-05-31	凯莫森特里克斯股份有限公司	免疫调节剂化合物
WO2018093484A1 (en)	2016-10-11	2018-05-24	Duke University	Lasofoxifene treatment of er+ breast cancer
CN111107858A (zh) *	2017-06-19	2020-05-05	美商生命科学公司	性功能障碍的治疗和性生活质量的改善
CA3070794A1 (en)	2017-07-28	2019-01-31	Chemocentryx, Inc.	Immunomodulator compounds
KR102670486B1 (ko)	2017-08-08	2024-05-28	케모센트릭스, 인크.	마크로사이클릭 면역조절제
EP3755311B1 (de)	2018-02-22	2026-01-28	ChemoCentryx, Inc.	Indanamine als pd-l1-antagonisten
CN117771239A (zh)	2018-04-10	2024-03-29	杜克大学	乳腺癌的拉索昔芬治疗
KR102132554B1 (ko) *	2019-02-25	2020-07-09	가톨릭대학교 산학협력단	랄록시펜을 유효성분으로 함유하는 전신경화증의 예방 또는 치료용 약학적 조성물
US11872217B2 (en)	2019-07-10	2024-01-16	Chemocentryx, Inc.	Indanes as PD-L1 inhibitors
JP7369437B2 (ja) *	2019-09-27	2023-10-26	国立大学法人三重大学	評価システム、評価方法、学習方法、学習済みモデル、プログラム
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996021656A1 (en) *	1995-01-09	1996-07-18	Pfizer, Inc.	Estrogen agonists/antagonists

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3274213A (en)	1961-09-05	1966-09-20	Upjohn Co	Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3396169A (en)	1966-10-26	1968-08-06	Upjohn Co	Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
US3234090A (en)	1962-09-10	1966-02-08	Ciba Geigy Corp	Pharmaceutical compositions comprising saturated basic ethers
US3862232A (en)	1963-07-03	1975-01-21	Upjohn Co	1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3293263A (en)	1963-12-09	1966-12-20	Upjohn Co	Diphenylbenzocycloalkenes
US3522319A (en)	1964-01-23	1970-07-28	Ciba Geigy Corp	Phenol substituted tetrahydronaphthalenes useful as estrogenics
IL23284A (en) *	1964-05-01	1969-01-29	Upjohn Co	Derivatives of 1,2-diphenyl-3,4-dihydronaphthalenes
US3320271A (en)	1964-06-01	1967-05-16	Upjohn Co	1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
US3483293A (en)	1967-12-15	1969-12-09	Upjohn Co	Method for controlling birds and rodents
US3567737A (en) *	1968-01-02	1971-03-02	Upjohn Co	Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
US3875242A (en) *	1968-01-02	1975-04-01	Upjohn Co	Compounds and process for preparing the same
US4133814A (en)	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
CA1116823A (en) *	1978-05-19	1982-01-26	Gregory C. Bockno	Crimped, high-strength rayon yarn and method for its preparation
DE3046719C2 (de) *	1980-12-11	1983-02-17	Klinge Pharma GmbH, 8000 München	1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4380635A (en)	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
US4358593A (en)	1981-04-03	1982-11-09	Eli Lilly And Company	Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US4859585A (en) *	1986-04-17	1989-08-22	Trustees Of Tufts College	In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
SE452551B (sv)	1986-05-27	1987-12-07	Camurus Ab	Artikel belagd med heparinbaserat material samt forfarande for dess framstellning
DE3733306C1 (de)	1987-10-02	1989-03-02	Judo Wasseraufbereitung	Rueckspuelfilter
JPH04312526A (ja) *	1991-04-09	1992-11-04	Fujisawa Pharmaceut Co Ltd	骨疾患治療剤
DE4117512A1 (de)	1991-05-25	1992-11-26	Schering Ag	2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
JP3157882B2 (ja)	1991-11-15	2001-04-16	帝国臓器製薬株式会社	新規なベンゾチオフエン誘導体
US5364791A (en) *	1992-05-14	1994-11-15	Elisabetta Vegeto	Progesterone receptor having C. terminal hormone binding domain truncations
TW366342B (en) *	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) *	1992-12-22	2000-03-01	Lilly Co Eli	New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en)	1993-03-19	1996-01-09	Eli Lilly And Company	Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
ATE157869T1 (de) *	1993-06-24	1997-09-15	Lilly Co Eli	Antiöstrogene 2-phenyl-3-aroylbenzothiophene als hypoglykämische mittel
US6756388B1 (en)	1993-10-12	2004-06-29	Pfizer Inc.	Benzothiophenes and related compounds as estrogen agonists
US5441964A (en)	1993-10-15	1995-08-15	Eli Lilly And Company	Methods for inhibiting bone loss using substituted benzothiophene
US5457116A (en) *	1993-10-15	1995-10-10	Eli Lilly And Company	Methods of inhibiting uterine fibrosis
KR950010891A (ko) *	1993-10-15	1995-05-15	피터 지. 스트링거	내성 종양을 치료하는 방법
US5391557A (en) *	1993-10-15	1995-02-21	Eli Lilly And Company	Methods for the treatment of peri-menopausal syndrome
US5418252A (en) *	1993-10-15	1995-05-23	Eli Lilly And Company	Method for inhibiting cartilage degradation
US5461065A (en) *	1993-10-15	1995-10-24	Eli Lilly And Company	Methods for inhibiting endometriosis
US5457113A (en) *	1993-10-15	1995-10-10	Eli Lilly And Company	Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US6417198B1 (en) *	1993-12-21	2002-07-09	Eli Lilly And Company	Methods of inhibiting CNS problems in post-menopausal women
US5389670A (en) *	1993-12-21	1995-02-14	Eli Lilly Company	Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5476862A (en) *	1993-12-21	1995-12-19	Eli Lilly And Company	Methods of increasing thrombomodulin expression
US5552415A (en) *	1993-12-21	1996-09-03	Eli Lilly And Company	Method of inhibiting Alzheimer's Disease
US5447941A (en) *	1993-12-21	1995-09-05	Eli Lilly And Company	Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5446053A (en) *	1993-12-21	1995-08-29	Eli Lilly And Company	Methods of inhibiting dysfunctional uterine bleeding
US5521198A (en) *	1993-12-21	1996-05-28	Eli Lilly And Company	Methods of inhibiting autoimmune diseases
US5451590A (en) *	1993-12-21	1995-09-19	Eli Lilly & Co.	Methods of inhibiting sexual precocity
US5708009A (en) *	1993-12-21	1998-01-13	Eli Lilly And Company	Methods of inhibiting myeloperoxidase activity
US5461064A (en) *	1993-12-21	1995-10-24	Eli Lilly And Company	Methods of inhibiting atrophy of the skin and vagina
US5534526A (en) *	1993-12-21	1996-07-09	Eli Lilly And Company	Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
AU8155694A (en) *	1993-12-21	1995-06-29	Eli Lilly And Company	Methods of inhibiting obsessive-compulsive and consumptive disorders
US5439931A (en) *	1993-12-21	1995-08-08	Eli Lilly And Company	Method for increasing libido in post-menopausal women
US5441966A (en) *	1993-12-21	1995-08-15	Eli Lilly And Company	Methods of inhibiting Turner's syndrome
US5593987A (en) *	1993-12-21	1997-01-14	Eli Lilly And Company	Methods of inhibiting breast disorders
US5462950A (en) *	1993-12-21	1995-10-31	Eli Lilly And Company	Methods of treating menstrual symptoms and compositions therefore
US5462949A (en) *	1993-12-21	1995-10-31	Eli Lilly And Company	Methods of inhibiting fertility in women
US5672610A (en) *	1993-12-21	1997-09-30	Eli Lilly And Company	Methods of increasing macrophage function
CZ286365B6 (cs) *	1993-12-21	2000-03-15	Eli Lilly And Company	Farmaceutický prostředek pro inhibici LDL oxidace a atherosklerosy
US5439923A (en) *	1993-12-21	1995-08-08	Eli Lilly And Company	Method of inhibiting seborrhea and acne
US5596004A (en) *	1993-12-21	1997-01-21	Eli Lilly And Company	Methods of inhibiting male infertility
CZ321394A3 (en) *	1993-12-21	1995-08-16	Lilly Co Eli	Pharmaceutical preparation for inhibiting woman hirsutism and alopecia
US5441965A (en) *	1993-12-21	1995-08-15	Eli Lilly And Company	Methods of inhibiting thrombin
US5451589A (en) *	1993-12-21	1995-09-19	Eli Lilly And Company	Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5384332A (en) *	1994-05-11	1995-01-24	Eli Lilly And Company	Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) *	1994-05-11	1995-10-03	Eli Lilly And Company	Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5470883A (en) *	1994-05-23	1995-11-28	Stromberg; Brent V.	Method of treating peripheral vasoconstriction with tamoxifen citrate
US5441986A (en) *	1994-07-19	1995-08-15	Pfizer Inc.	Estrogen agonists as remedies for prostate and cardiovascular diseases
US5550163A (en) *	1994-08-03	1996-08-27	Allergan, Inc.	Method for reducing filtrate waste in a manufacturing process of a pharmaceutical product containing benzalkonium chloride
US5434166A (en) *	1994-08-22	1995-07-18	Eli Lilly And Company	Methods of inhibiting demyelinating and desmyelinating diseases
US5492921A (en)	1994-09-20	1996-02-20	Eli Lilly And Company	Benzothiophene compounds, compositions, and methods for inhibiting aortal smooth muscle proliferation
US5510357A (en)	1995-02-28	1996-04-23	Eli Lilly And Company	Benzothiophene compounds as anti-estrogenic agents
US5532382A (en)	1995-03-13	1996-07-02	Eli Lilly And Company	Benzothiophenes substituted at the 3-carbonyl
US5567828A (en)	1995-06-07	1996-10-22	Eli Lilly And Company	Compounds and compositions with nitrogen-containing non-basic side
UA51676C2 (uk) *	1995-11-02	2002-12-16	Пфайзер Інк.	(-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120268A0 (en)	1996-02-28	1997-06-10	Pfizer	Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en)	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
CN1228775A (zh)	1996-05-14	1999-09-15	葛兰素集团有限公司	作为时间生物学药物的苯并呋喃和苯并吡喃
CA2215647A1 (en) *	1996-10-24	1998-04-24	Eli Lilly And Company	Naphthyl compounds, compositions, and methods
AU5550298A (en) *	1997-01-29	1998-08-25	Novo Nordisk A/S	Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
SK285991B6 (sk)	1997-04-25	2008-01-07	Pfizer Inc.	Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
ZA985543B (en)	1997-06-27	1998-12-28	Smithkline Beecham Corp	Novel methods
EP1027057A4 (de)	1997-10-28	2003-01-02	Vivus Inc	Behandlung von weibliche sexuelle störungen
US5877216A (en)	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
CZ299198B6 (cs)	1999-06-11	2008-05-14	Watson Pharmaceuticals, Inc.	Souprava a lécivo pro zlepšování zdravotního stavu žen na bázi testosteronu
US6245819B1 (en)	2000-07-21	2001-06-12	Hormos Medical Oy, Ltd.	Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

1997
- 1997-02-20 IL IL12026697A patent/IL120266A/xx not_active IP Right Cessation
- 1997-02-21 AT AT01101953T patent/ATE396728T1/de not_active IP Right Cessation
- 1997-02-21 DK DK01101953T patent/DK1106179T3/da active
- 1997-02-21 DE DE69738740T patent/DE69738740D1/de not_active Expired - Lifetime
- 1997-02-21 PT PT01101953T patent/PT1106179E/pt unknown
- 1997-02-21 EP EP01101953A patent/EP1106179B1/de not_active Expired - Lifetime
- 1997-02-21 PT PT97301147T patent/PT792641E/pt unknown
- 1997-02-21 US US08/803,733 patent/US6107331A/en not_active Expired - Lifetime
- 1997-02-21 ES ES97301147T patent/ES2159811T3/es not_active Expired - Lifetime
- 1997-02-21 DE DE69705874T patent/DE69705874T2/de not_active Expired - Lifetime
- 1997-02-21 DK DK97301147T patent/DK0792641T3/da active
- 1997-02-21 AT AT97301147T patent/ATE203670T1/de not_active IP Right Cessation
- 1997-02-21 EP EP97301147A patent/EP0792641B1/de not_active Expired - Lifetime
- 1997-02-21 ES ES01101953T patent/ES2305003T3/es not_active Expired - Lifetime
- 1997-02-26 CA CA002198578A patent/CA2198578C/en not_active Expired - Lifetime
- 1997-02-27 ZA ZA971714A patent/ZA971714B/xx unknown
- 1997-02-27 MY MYPI97000784A patent/MY125602A/en unknown
- 1997-02-27 AU AU14979/97A patent/AU703473B2/en not_active Ceased
- 1997-02-27 KR KR1019970006288A patent/KR970061254A/ko not_active Ceased
- 1997-02-28 CN CN97103414A patent/CN1122513C/zh not_active Expired - Lifetime
- 1997-02-28 CN CNA031412289A patent/CN1515256A/zh active Pending
- 1997-02-28 JP JP9045652A patent/JPH107563A/ja active Pending
1999
- 1999-05-19 US US09/314,758 patent/US6274618B1/en not_active Expired - Lifetime
2000
- 2000-02-23 US US09/511,806 patent/US6355670B1/en not_active Expired - Lifetime
2001
- 2001-03-09 US US09/803,516 patent/US6403611B2/en not_active Expired - Lifetime
- 2001-09-11 GR GR20010401440T patent/GR3036583T3/el not_active IP Right Cessation
- 2001-11-15 US US09/999,291 patent/US6613796B2/en not_active Expired - Lifetime
2002
- 2002-04-26 US US10/133,006 patent/US6911456B2/en not_active Expired - Fee Related
2003
- 2003-07-07 US US10/615,282 patent/US20040009994A1/en not_active Abandoned
2004
- 2004-11-01 IL IL16496704A patent/IL164967A0/xx unknown
2005
- 2005-03-03 US US11/071,955 patent/US20050148625A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996021656A1 (en) *	1995-01-09	1996-07-18	Pfizer, Inc.	Estrogen agonists/antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU784439B2 (en) *	2000-01-12	2006-04-06	Pfizer Products Inc.	Compositions and methods of treatment for conditions responsive to testosterone elevation

Also Published As

Publication number	Publication date
US6355670B1 (en)	2002-03-12
CN1515256A (zh)	2004-07-28
EP1106179A2 (de)	2001-06-13
US6613796B2 (en)	2003-09-02
US20030220349A1 (en)	2003-11-27
US20050148625A1 (en)	2005-07-07
AU1497997A (en)	1997-09-04
DE69738740D1 (de)	2008-07-10
CN1122513C (zh)	2003-10-01
DE69705874T2 (de)	2001-11-15
DK0792641T3 (da)	2001-10-08
MY125602A (en)	2006-08-30
IL120266A (en)	2005-05-17
ES2159811T3 (es)	2001-10-16
DK1106179T3 (da)	2008-08-18
US20020091121A1 (en)	2002-07-11
ATE396728T1 (de)	2008-06-15
IL120266A0 (en)	1997-06-10
IL164967A0 (en)	2005-12-18
DE69705874D1 (de)	2001-09-06
PT1106179E (pt)	2008-07-28
ATE203670T1 (de)	2001-08-15
CA2198578C (en)	2002-06-11
CN1167617A (zh)	1997-12-17
EP0792641A1 (de)	1997-09-03
KR970061254A (ko)	1997-09-12
CA2198578A1 (en)	1997-08-28
HK1001963A1 (en)	1998-07-24
US6274618B1 (en)	2001-08-14
MX9701530A (es)	1998-06-30
US6107331A (en)	2000-08-22
US20040009994A1 (en)	2004-01-15
EP0792641B1 (de)	2001-08-01
US6403611B2 (en)	2002-06-11
EP1106179B1 (de)	2008-05-28
ZA971714B (en)	1997-08-27
US6911456B2 (en)	2005-06-28
EP1106179A3 (de)	2004-01-07
JPH107563A (ja)	1998-01-13
US20010018451A1 (en)	2001-08-30
PT792641E (pt)	2001-11-30
ES2305003T3 (es)	2008-11-01
GR3036583T3 (en)	2001-12-31

Publication	Publication Date	Title
AU703473B2 (en)	1999-03-25	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
RU2143897C1 (ru)	2000-01-10	Способы подавления атрофии кожи и влагалища
CA2198562C (en)	2002-09-10	Method of treating conditions with estrogen agonists
JPH06234632A (ja)	1994-08-23	ベンゾチオフェン類を含有する医薬組成物
KR20010098650A (ko)	2001-11-08	여성 성기능장애를 치료하기 위한 조성물 및 방법
US6448276B1 (en)	2002-09-10	Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists
AU707455B2 (en)	1999-07-08	Use of (E)-1-{4'-(2-alkylaminoethioxy)phenyl}-1- (3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
HUT71481A (en)	1995-11-28	Pharmaceutical compositions for treatment of seborrea and acne containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
JPH07215865A (ja)	1995-08-15	閉経後女性の性欲を増進するための方法
CA2279747A1 (en)	2000-02-06	Estrogen agonists/antagonists
MXPA97001530A (en)	1998-10-30	Use of estrogen antagonists and estrogen agonists to inhibit pathologi conditions
EP0659424A1 (de)	1995-06-28	2-Phenyl-3-Azoylbenzothiopene zur Behandlung von Männerunfruchtbarkeit
HK1001963B (en)	2004-01-30	Use of compounds in the preparation of a medicament for the inhibition of a pathological condition
MXPA97001529A (en)	1998-10-30	Use of (e) -1- [4 '- (2-alkylaminoetoxy) phenyl] -1- (3'-hydroxypenyl) -2-fenilbut-1-enos to inhibit pathologi disorders
HK1001964A (en)	1998-07-24	Use of (e)-1-[4'(2-alkylaminoethioxy)phenyl]-1-(3'hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
HK1064279A (en)	2005-01-28	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions

AU703473B2 - Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=21758830

Family Applications (1)

Country Status (16)

Cited By (1)

Families Citing this family (48)

Citations (1)

Family Cites Families (84)

Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents